What the New Cervical Cancer Mortality Data Shows About Age at HPV Vaccination

Between 2020 and 2024, no woman aged 20 to 24 in England died of cervical cancer. Historical rates predicted roughly 23 deaths. The analysis, published in The Lancet, is the first robust national-level evidence, that HPV vaccination reduces cervical cancer mortality and not only incidence.

The zero should be read carefully, and the authors say so directly: with a baseline rate that low, chance contributes, and a single death would change the figure. The real findings sit underneath it. Against a 2000 to 2014 baseline, mortality fell 80% (95% CI 51 to 94) in women aged 20 to 24 and 69% (55 to 79) in women aged 25 to 29. The estimated relative risk reduction in vaccinated women was 100% in both the 20 to 24 group (81 to 100) and the 25 to 29 group (89 to 100). Roughly 200 deaths are estimated to have been prevented through the end of 2024, a figure expected to rise substantially as vaccinated cohorts age.

The Scottish incidence data adds the detail that matters most at the point of care. In a linked national cohort of women born between 1988 and 1996, no cases of invasive cervical cancer were recorded among those immunized at age 12 or 13, irrespective of dose number, against 8.4 per 100,000 person-years in unvaccinated women. Effectiveness declined sharply with age at immunization: 86.2% (71.8 to 93.2) at ages 14 to 16, and 38.9% (3.2 to 61.5) at 17 to 18. Adjusted effectiveness for complete vaccination at 14 or older was 73.8% (58.9 to 83.4).

That gradient reflects mechanism rather than adherence. These vaccines are prophylactic and do not clear established infection, so effectiveness depends on immunization preceding exposure.

The Scottish team also looked at socioeconomic status, dividing the population into five bands from most to least deprived. Cervical cancer was most common in the most deprived fifth, and that group saw the largest absolute benefit from vaccination: 13.1 cases per 100,000 person-years among unvaccinated women, against 2.29 among those who completed three doses. The patients with the most to gain from finishing the series are often the least likely to.

Delay costs twice over. A patient who starts before 15 needs two doses, six to 12 months apart. Starting at 15 or older means three doses across roughly six months, one more visit to schedule at exactly the age when effectiveness is already falling. Immunocompromised patients aged 9 through 26 need three doses regardless of when they start.

Plans already track this. The HEDIS adolescent immunization measure requires a completed HPV series by the 13th birthday, and HPV is usually where plans score worst on it. But that’s a once-a-year population number. It will not tell you that the patient in front of you had one dose in March and never came back.

Clinical takeaway: the visit between ages 9 and 13 now carries quantifiably more preventive weight than the same conversation three or four years later, and the difference is large enough to change how the opportunity is prioritized. Provider recommendation remains the strongest modifiable factor in the literature: in a 2021 meta-analysis, 24% of patients initiated HPV vaccination without a recommendation from their provider, against 60% of those who received one, and recommendation was also associated with better series completion. Track completion rather than initiation, since national 2024 rates were 79.1% for a first dose and 64.3% up to date, and the effectiveness data above was built on completed courses. Where a patient's history looks incomplete, the state immunization registry may hold doses your own record does not. And continue reinforcing cervical screening in vaccinated patients, since current vaccines cover an estimated 85% of HPV-positive invasive cervical cancers in the Scottish population studied.